Lantern Pharma Inc. (Nasdaq: LTRN)

??In case you missed it - Lantern Pharma Webinar Wednesday -childhood cancer awareness month webinar- LP-184 with three additional rare pediatric disease designation insights rare children’s cancers is now available on Lantern Pharma Inc. (Nasdaq: LTRN)‘s #Youtube Channel! https://lnkd.in/e8G7BpGs Thank you everyone for joining?this month’s Lantern Pharma Webinar Wednesday! We look forward to your continued excitement and engagement in upcoming Webinar Wednesdays- happening every month, on the last Wednesday of each month. Here are highlights of the webinar: ???Childhood cancer awareness month webinar- LP-184 with three additional rare pediatric disease designation insights rare children’s cancers???Panna gives an overview of the current state of childhood cancers and our recent announcement on receiving three additional RPDD for LP-184 ??Dr. Reggie walks through the three different indications that we received RPDD for - which are 1. malignant rhabdoid tumors (MRT) 2. rhabdomyosarcoma (RMS), and 3. Hepatoblastoma. ??Panna shares preclinical data for LP-184 that led to the RPDD grant Follow us to join in exploring the forefront of cancer research and treatment by accessing these insightful webinars for free!

??Happening TOMORROW, September 25th, 1PM Eastern time?? Register Now for Childhood Cancer Awareness Month LIVE #Webinar https://bit.ly/47BcDce Join Lantern Pharma Inc. (Nasdaq: LTRN)'s CEO and President Panna Sharma and VP of Clinical development Dr. Reggie Ewesuedo for a LIVE WEBINAR - where they are doing a deeper dive into our recent announcement on receiving three?additional FDA Rare Pediatric Disease Designations for our drug candidate LP-184 in ultra-rare children's cancers. Register now to join a FREE LIVE Webinar TOMORROW! https://bit.ly/47BcDce https://bit.ly/47BcDce #ChildhoodCancerAwarenessMonth

??Register Now for Childhood Cancer Awareness Month Lantern Pharma Inc. (Nasdaq: LTRN) Webinar Wednesday! https://bit.ly/47BcDce Happening This Wednesday, September 25th, 1PM Eastern time, our CEO and President Panna Sharma and VP of Clinical development Dr. Reggie Ewesuedo will be doing a deeper dive into our recent announcement on receiving three?additional FDA Rare Pediatric Disease Designations for our drug candidate LP-184 in ultra-rare children's cancers. Register now to join a FREE LIVE #WEBINAR ??? this wednesday! https://bit.ly/47BcDce Read the full PR: https://bit.ly/47DKl0J Visit our website: www.lanternpharma.com #ChildhoodCancerAwarenessMonth #PediatricCancers #Childhoodcancers #RareCancers #Oncology #Research #CEO

?? Exciting news at Lantern Pharma Inc. (Nasdaq: LTRN)! Today we announced that we've been granted?three?additional FDA Rare Pediatric Disease Designations for our drug candidate LP-184 in three ultra-rare children's cancers; malignant rhabdoid tumors (MRT), rhabdomyosarcoma (RMS), and hepatoblastoma. This adds to the previous designation for #ATRT, reinforcing LP-184’s potential to treat ultra-rare childhood cancers. With our AI-driven approach, we're committed to making a significant impact on pediatric cancer treatment and accelerating the journey to new, life-saving therapies. Learn more about this milestone and our dedication to transforming hope into reality. Read the full PR: https://bit.ly/47DKl0J Visit our website: www.lanternpharma.com #Childhoodcancerawarenessmonth #ChildhoodCancer #PediatricCancer #Oncology #Drugdevelopment

?Did you know... September is #ChildhoodCancerAwarenessMonth. September is a time to honor the brave children fighting cancer and to raise awareness about the urgent need for better treatments. Together, we can spark hope, spread awareness, and make a difference. ?? Check out our past webinar featuring a leading expert in pediatric cancer research, Peter Houghton, Ph.D., Professor & Principal Investigator at UT Health SA, Greehey CCRI. In the podcast, Dr. Houghton discussed .. ??the disparities and hurdles that currently exist in pediatric cancer research ??Collboration with Lantern advancing therapies for childhood cancer - LP-184 and LP-284 ??Clinical trial design for pediatric cancers compared to adults ...and much more! Check out the full episode here: https://lnkd.in/eaU2qJxC Follow us for upcoming webinars and exciting updates on Lantern Pharma Inc. (Nasdaq: LTRN)'s continuous efforts on finding better options for #PediatricCancer! #Childhoodcancerawareness #GOGOLDFORCHILDHOODCANCER

“By harnessing the power of AI and a commitment to high-quality, actionable data, Lantern is paving the way for more rapid, cost-effective, and targeted drug development.” ?? New blog alert! Check out this article by DrugBank featuring Lantern Pharma Inc. (Nasdaq: LTRN)’s innovative use of AI in oncology drug development. The article covers: ??How Lantern is revolutionizing oncology with RADR?, a machine learning platform for predicting patient responses and optimizing treatments. ??What sets RADR? apart in accelerating effective drug development. ??Real-world patient outcomes transformed by the platform. ??Future RADR? applications, including immuno-oncology and antibody-drug conjugates (ADCs). ... and much more! ?? Read it here: https://bit.ly/3MMyLHd #Oncology #AIinHealthcare #DrugDevelopment #DrugDiscovery

??New Podcast Alert?? Innovating Health Podcast of Health Wildcatters "Founder Story: Navigating the Path to Exit," is now live! ????? In this episode, Dr. Hubert Zajicek, MD, MBA, sits down with our President and CEO, Panna Sharma, to discuss his remarkable journey at the helm of Lantern Pharma Inc. (Nasdaq: LTRN). Panna shares his unique insights on navigating the complexities of the healthcare industry, leading Lantern Pharma to a successful public exit, and what’s next in the future of biotech innovation. ??Tune in now and learn how Lantern Pharma is leveraging A.I., machine learning, and genomics to revolutionize oncology drug discovery, cutting down costs and speeding up development timelines. ?? Spotify: https://lnkd.in/gtTcPkxS? ?? Apple Music: https://lnkd.in/g9uwYwSm? ?? Website: https://lnkd.in/giEu9t2U

??In case you missed it - #SOHO2024 poster is now up! Last week, we presented at the Society of Hematologic Oncology 2024 annual meeting. Our scientist Jianli Zhou, Ph.D., shared some of the innovative work powered by Lantern Pharma Inc. (Nasdaq: LTRN)'s AI platform RADR? and were able to connect with the #CancerResearch community. Leveraging Artificial Intelligence, Machine Learning, and genomics, we are working towards transforming the cost, pace, and timeline of oncology drug discovery and development. In our poster presented at #SOHO, we highlighted updates on our drug candidate LP-284, currently in Phase 1 #clinicaltrial for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas and Solid Tumors. Check out the poster at our website: https://bit.ly/3yIRBLW #Oncology #OncologyResearch #2024SOHO

#SOHO2024 poster is now up! Yesterday, we presented at the #Soho2024 Annual Meeting. Our scientist Jianli Zhou, Ph.D., shared some of the innovative work powered by Lantern Pharma Inc. (Nasdaq: LTRN)'s AI platform RADR? and were able to connect with the #CancerResearch community. Leveraging Artificial Intelligence, Machine Learning, and genomics, we are working towards transforming the cost, pace, and timeline of oncology drug discovery and development. In our poster presented at #SOHO, we highlighted updates on our drug candidate LP-284, currently in Phase 1?#clinicaltrial for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas and Solid Tumors Check out the poster at our website: https://bit.ly/3yIRBLW #oncology #drugdiscovery #drugdevelopment #oncologyresearch #AI #Genomics #ML #ArtificialIntelligence #Machinelearning #Datascience #24SOHO

??In case you missed it - Lantern Pharma Webinar Wednesday - Harmonic? Phase 2 Clinical Trial for Never Smokers with NSCLC- Preliminary patient data and clinical readouts is now available on Lantern Pharma Inc. (Nasdaq: LTRN)'s #Youtube Channel! https://lnkd.in/eaxxtdQZ Thank you everyone for joining?this month’s Lantern Pharma Webinar Wednesday! We look forward to your continued excitement and engagement in upcoming Webinar Wednesdays- happening every month, on the last Wednesday of each month. Here are highlights of the webinar: ???Harmonic? Phase 2 Clinical Trial for Never Smokers with NSCLC- Preliminary patient data and clinical readouts ??Dr. Reggie Ewesuedo gives an overview of the Harmonic phase 2 clinical trial in never smokers with non-small cell lung cancer.? ??He shares the preliminary data of 7 initial patients of the safety lead-in phase of the trial. ???Dr. Reggie Ewesuedo talks about the expansion phase of the trial and what is coming up - including expansion to the APAC countries starting from Japan and Taiwan. Follow us to join in exploring the forefront of cancer research and treatment by accessing these insightful webinars for free!